CPRX Stock Analysis: Buy, Sell, or Hold?
CPRX - Catalyst Pharmaceutical Inc.
$31.17
0.64 (2.11%)
▲
5d:
+10.79%
30d:
+23.13%
90d:
+30.34%
HOLD
MODERATE Confidence
Analysis Updated: May 7, 2026 12:00 AM ET
Earnings: May 11, 2026
2d
Smart Money Distribution
CPRX is up 6.9% this week, but smart money is buying puts. Top strike: $20 2026-06-18 with 1,286 OI. Put ratio: 76% View Scanner →
Strength: 6.1/10
Get Alerted When CPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: CPRX is 7.9% above its trading range ($28.89). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: CPRX is 7.9% above its trading range ($28.89). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$37.96
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$23.57
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CPRX is currently trading at $31.16, which is considered extended relative to its 30-day fair value range of $24.78 to $28.89. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.9) compared to its historical average (8.7). At these levels, the market is pricing in 4.4% annual earnings growth.
Technical Outlook: Technically, CPRX is in a strong downtrend. Immediate support is located at $26.50, while resistance sits at $32.56.
Market Sentiment: CPRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CPRX is in a strong downtrend. Immediate support is located at $26.50, while resistance sits at $32.56.
Market Sentiment: CPRX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$24.78 -
$28.89
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
55.7%
All Signals
- BEARISH: Price extended above range (+7.9% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($34.14)
- BULLISH: Expecting earnings turnaround to 4.4% growth with 7.6% revenue growth
Trading Range Analysis
30-Day Trading Range
$24.78 -
$28.89
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$26.50
Resistance Level
$32.56
Current Trend
Strong Downtrend
Technical data as of
May 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.94
Wall Street Target
$34.14
(+9.6%)
Revenue Growth (YoY)
7.6%
Earnings Growth (YoY)
-6.4%
Profit Margin
36.4%
Valuation Premium vs History
+4.4% premium
PE vs Historical
9.9 vs 8.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.4%
(market-implied from PE analysis)
1-Year Target
$32.54
(+4%)
2-Year Target
$33.97
(+9%)
3-Year Target
$35.46
(+14%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$31.04
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 9.7%)
$90.74
(+191%)
Base:
(SPY PE: 9.9, Growth: 9.7%)
$41.11
(+32%)
Bear:
(PE: 8.4, Growth: 9.7%)
$34.94
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 18.17 | Current EPS (TTM): $1.68
Bull Case
$62.66
(+101%)
Analyst growth 86.6%, PE expands to 20.0
Base Case
$56.96
(+83%)
Market implied 86.6%, PE stable at 18.2
Bear Case
$20.75
(-33%)
Severe decline -20.0%, PE contracts to 15.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 08, 2026 7:08 AM ET
Data refreshes hourly during market hours. Next update: 8:08 AM
Data refreshes hourly during market hours. Next update: 8:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Molly Harper
SELL
26746 shares
2025-12-12
Carmen Jeffrey Del
SELL
10983 shares
2025-11-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 56 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 43 HOLD |
